SUPPLEMENTARY MATERIAL - APPENDIX

EQUATION SEARCH

Pubmed

("thrombosis"[MeSH Terms] OR "thrombosis"[All Fields]) OR ("Peripheral Arterial Disease"[Mesh] or "ischemia"[All Fields] OR "Ischemia"[Mesh] OR "Mesenteric Ischemia"[Mesh] OR "stroke"[MeSH Terms] OR "stroke"[All Fields] OR "myocardial infarction"[MeSH Terms] OR "infarction"[All Fields] OR "myocardial infarction"[All Fields] OR "acute coronary syndrome"[MeSH Terms] OR "acute coronary syndrome"[All Fields] OR "venous thrombosis"[MeSH Terms] OR "deep venous thrombosis"[All Fields] OR "venous thromboembolism"[MeSH Terms] OR "DVT" [All Fields] "thromboembolism"[All Fields] OR "venous thromboembolism"[All Fields] OR "pulmonary embolism"[MeSH Terms] OR "pulmonary embolism"[All Fields]) AND (("severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "sars cov 2"[All Fields]) OR (novel[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) OR nCoV[All Fields] OR ("severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "2019 ncov"[All Fields]) OR ("COVID-19"[All Fields] OR "COVID-2019"[All Fields] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "2019-nCoV"[All Fields] OR "SARS-CoV-2"[All Fields] OR "2019nCoV"[All Fields] OR (("Wuhan"[All Fields] OR ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12[PDAT] OR 2020[PDAT])))) Sort by: Most Recent

Embase

('thrombosis'/exp OR 'peripheral occlusive artery disease'/exp OR 'ischemia'/exp OR 'cerebrovascular accident'/exp OR 'infarction'/exp OR 'acute coronary syndrome'/exp OR 'vein thrombosis'/exp OR 'deep vein thrombosis'/exp OR 'venous thromboembolism'/exp OR 'thromboembolism'/exp OR 'lung embolism'/exp) AND ('severe acute respiratory syndrome coronavirus 2'/exp OR 'sars-related coronavirus'/exp OR 'coronavirus infection'/exp OR 'coronavirus disease 2019'/exp)

Google Scholar

Stroke OR myocardial OR infarction OR thrombosis OR DVT OR "pulmonary embolism"

AND

"covid-19" OR “SARS-CoV-2” or “coronavirus”

FIGURES

Figure S1 – Funnel plot for venous (A) and arterial (B) thromboembolism. The visual inspection suggested visual plot asymmetry, especially for venous thromboembolism.

Figure S2 – Forest plot showing the weighted pooled prevalence of pulmonary embolism according to patient population.
ICU: intensive care unit

Figure S3 – Forest plot showing the weighted pooled prevalence of deep venous thrombosis according to patient population.
ICU: intensive care unit

Figure S4 – Forest plot showing the weighted pooled prevalence of subsegmental pulmonary embolism.

Figure S5 – Forest plot showing the weighted pooled prevalence of leg proximal and distal deep venous thrombosis and other venous thrombosis including superficial and catheter related thrombosis.
DVT : deep venous thrombolism.

Figure S6 – Forest plot showing the weighted pooled prevalence of proximal deep venous thrombosis according to patient population.
ICU: intensive care unit

Figure S7 – Forest plot showing the weighted pooled prevalence of venous thromboembolism according to study design.

Table 1 – Study characteristics

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Aleva et al.[57]	Netherlands	100%	50	86	NA, C, m	RT-PCR	66%	65	Symptomatic testing	26%	100%	NA
Alharthy et al.[58]	USA	100%	85	28	P, C, m	RT-PCR	43%	43	Asymptomatic screening (DVT), Symptomatic testing (PE)	28%	100%	6400
Annie et al.[59]	Intern.	NA	9358	>17	R, C, M	RT-PCR	40%	<50	NA	1%	NA	NA
Aversa et al.[60]	USA	34%	27	44	R, C, m**	RT-PCR	50%	65	Symptomatic testing	41%	NA	2600
Alonso-Fernandez et al.[61]	Spain	38%	30	20	P, C, m@	RT-PCR	63%	65	Asymptomatic screening	0%	44%	2400
Al-Samkari et al.[17]	USA	36%	400	8	R, NC, M+	RT-PCR	58%	62	Symptomatic testing	8%	100%	NA
Artifoni et al.[62]	France	18%	71	NA	R, C, M	RT-PCR or CT-scan	61%	64	Asymptomatic screening	NA	99%	790
Beigel et al.[63]	Intern.	44%	1063	29	P, C, M	RT-PCR	64%	59	Symptomatic testing	NA	NA	NA
Benito et al.[64]	Spain	NA	1275	NA	P, C, m	RT-PCR	NA	NA	Symptomatic testing	12%	NA	NA

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Betoule et al.[65]	France	19%	76	NA	NA, R, m	RT-PCR	50%	62	NA	4%	NA	NA
Beun et al.[66]	Netherlands	100%	75	NA	NA, NA, m	NA	NA	61	NA	NA	NA	486
Beyls et al.[67]	France	100%	12	NA	NA, NA, m	RT-PCR	83%	62	Symptomatic testing	17%	100%	8300
Bilaloglu et al.[18]	USA	25%	3334	NA	NA, C, m	RT-PCR	61	64	Symptomatic testing	25%	NA	NA
Bompard et al.[68]	France	24%	135	27	R, NC, m	NA	70%	64	Symptomatic testing	12%	100%	1600
Bonnazi et al.	Italy	NA	942	NA	R, NC, m	NA	NA	NA	Symptomatic testing	NA	NA	NA
Cantador et al.[69]	Spain	NA	1419	NA	R, NA, m	NA	NA	NA	Symptomatic testing	NA	NA	NA
Campochiaro et al.[70]	Italy	33%	65	28	R, NA, m	RT-PCR	28%	62	Symptomatic testing	25%	NA	NA
Cattaneo et al.[4]	Italy	0%	64	9	R, NC, m	NA	55%	70	Asymptomatic screening	NA	100%	458
Cho et al.[71]	USA	NA	1170	NA	R, C, m	RT-PCR	NA	NA	Symptomatic testing	NA	NA	NA
Choi et al.[72]	USA	27%	1739	7	R, C, m	RT-PCR	59%	67	Symptomatic testing	18%	100%	565

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Cui et al.[15]	China	100%	81	14	R, NA, m	RT-PCR and CT-scan	46%	60	Symptomatic testing	10%	NA	1887
Desborough et al.[50]	UK	100%	66	30	R, C, m	NA	73%	59	Symptomatic testing	30%	100%	2400
Du et al.	China	NA	196	NA	R, C, m	RT-PCR	84%	62	Symptomatic testing	4%	NA	NA
Dubois-Silva et al.[73]	Spain	0%	171	NA	R, C, m	RT-PCR and serology	NA	NA	Symptomatic testing (PE), asymptomatic screening (DVT)	NA	NA	NA
Dumantepe et al.[74]	Turkey	NA	352	NA	R, C, m	RT-PCR	64%	56	Symptomatic testing	3%	100	1380
Espallargas et al.[75]	Spain	NA	910	NA	R, C, m	RT-PCR and CT-scan	NA	NA	Symptomatic testing	NA	NA	NA
Etkin et al.[76]	USA	14%	12630	7	R, C, M	NA	76%	67	Symptomatic testing	10%	NA	438
Fan et al.[77]	China	100%	86	35	R, NC, m	RT-PCR or serology	63%	67	Symptomatic testing	64%	56	9000
Fauvel et al.[78]	France	15%	1240	NA	R, C, M	RT-PCR and CT-scan	64%	64	Symptomatic testing	12%	71%	1642

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Fraissé et al.[51]	France	100%	92	NA	R, C, m	NA	79%	61	Symptomatic testing	41%	100%	2400
Freund et al.[79]	Intern.	NA	974	NA	R, NC, M	RT-PCR and CT-scan	NA	NA	Symptomatic testing	NA	NA	NA
Galaneo-Valle et al.[80]	Spain	NA	156	9	P, C, m	RT-PCR and CT-scan	NA	NA	Symptomatic testing	NA	NA	NA
Gervaise et al.	France	NA	146	8	R, C, m	RT-PCR and CT-scan	75%	62	CPTA series	15%	NA	3610
Giorgi-Pierfrancesc hi et al.[81]	Italy	NA	66	13	NA, NA, m	RT-PCR	46%	72	Asymptomatic screening	NA	96%	329
Friedmann et al.[82]	Canada	NA	99	NA	NA, NA, m	NA	NA	NA	NA	NA	NA	NA
Grandmaison et al.[83]	Switzerland	100%	29	NA	P, C, m	NA	65%	66	Asymptomatic screening	NA	88%	NA
Hanif et al.[84]	USA	35%	921	9	R, C, m	RT-PCR	62%	62	Symptomatic testing	NA	97%	3190
Helms et al.[36##]	France	100%	150	10	P, C, M	RT-PCR	81%	63	Symptomatic testing	9%	100%	2270

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Huet et al.[85]	France	8%	96	<20	P, C, m^{++}	RT-PCR and CT-scan	64%	NA	Symptomatic testing	NA	NA	NA
Hippensteel et al.[86]	USA	100%	91	26	R, NC, m	NA	58%	56	Symptomatic testing	43%	NA	NA
Inciardi et al.	Italy	12%	99	14	R, C, m	RT-PCR	80%	67	Symptomatic testing	26%	NA	576
Jimenez-Guiu et al.[87]	Spain	0%	57	9	P, C, m	RT-PCR and CT-scan	51%	57	Systematic testing	NA	100%	NA
Kartsios et al.[88]	UK	NA	1583	NA	R, C, m	RT-PCR	NA	NA	Systematic testing	NA	NA	NA
Klok et al.[53]	Netherlands	100%	184	14	NA, NA, M	RT-PCR	76%	64	Symptomatic testing	22%	100%	NA
Koleitat et al.[89]	USA	NA	135	7	R, C, m	RT-PCR	56%	63	DUS series	15%	84%	NA
Leonard-Lorant et al.[25##]	France	43%	106	30	P, C, m	RT-PCR and CT-scan	43%	64	Symptomatic testing	NA	47%	15385
Larsen et al.[90]	France	11%	35	40	NA, C, m$^{\mu}$	RT-PCR and CT-scan	77%	66	Asymptomatic screening	0%	80%	1220

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Lejeune et al.[91]	France	7%	42	11	R, C, m	RT-PCR and CT-scan	55%	65	Asymptomatic screening (DVT), symptomatic testing (EP)	5%	100%	1414
Lendorf et al.[92]	Denmark	18%	111	6	R, C, m	RT-PCR	56%	69	Symptomatic testing	14%	NA	1200
Llitjos et al.[5]	France	100%	26	NA	R, C, M	RT-PCR	77%	68	Asymptomatic screening	12%	100%	1750
Li et al.[93]	China	NA	219	NA	R, C, m	RT-PCR and CT-scan	41%	53	Symptomatic testing	NA	NA	NA
Lodigiani et al.	Italy	15%	388	10	R, C, m	NA	61%	69	Symptomatic testing	26%	79%	3000
Longchamp et al.[94]	Switzerland	100%	25	NA	P, C, m	RT-PCR	64%	68	Asymptomatic screening	NA	100%	2071
Longhitano et al.[95]	Italy	100%	62	NA	R, C, m	RT-PCR	NA	NA	Symptomatic testing	NA	100%	NA
Maatman et al.[96]	USA	100%	109	NA	R, C, M	RT-PCR	62%	61	Symptomatic testing	16%	100%	506
Marone et al.[97]	Italy	10%	101	NA	P, C, M	NA	NA	NA	DUS series	NA	NA	NA

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Mationi et al.[98]	Italy	0%	105	36	R, C, m	RT-PCR and CT-scan	58%	74	Symptomatic testing	21%	100%	1437
Mei et al.[99]	China	NA	256	14	R, NA, m	RT-PCR, gene assay, and CT-scan	56%	59	Symptomatic testing	6%	100%	510
Mestre-Gomez et al.[100]	Spain	0%	452	NA	R, C, m	WHO clinical criteria and RT-PCR	NA	NA	Symptomatic testing	NA	NA	NA
Middeldorp et al.[26]	Netherland	38%	198	>17	R, C, m	RT-PCR and CT-scan	66%	62	Symptomatic testing[£]	19%	94%	2000
Moll et al.[52]	USA	48%	210	7	R, NA, m	RT-PCR	48%	62	Symptomatic testing	17%	90%	NA
Monfardini et al.[101]	Italy	NA	1207	NA	R, C, m	RT-PCR	NA	NA	Symptomatic testing	NA	NA	NA
Mouhat et al.[102]	France	20%	349	NA	R, C, m	RT-PCR	67%	66	Symptomatic testing	NA	NA	1920
Mueller-Peltzer et al.[103]	Germany	100%	16	23	R, NC, m	RT-PCR	73	60	Asymptomatic screening	45%	NA	460

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Nahum et al.[104]	France	100%	34	NA	P, C, m	NA	78%	62	Asymptomatic screening	0%	100%	5100
Naygamon et al.[105]	USA	NA	1065	NA	R, C, M	RT-PCR	NA	NA	Symptomatic testing	NA	NA	NA
Pavoni et al.[106]	Italy	100%	44	30	R, NA, m	RT-PCR	64	64	Asymptomatic screening (DVT), symptomatic testing (EP)	21%	100%	NA
Patell et al.[107]	USA	51%	398	8	R, C, m	RT-PCR	49%	≈64	Symptomatic testing	21%	93%	NA
Piagnereli et al.[108]	Belgium	100%	19	19	NA, NA, m	RT-PCR	NA	58	Symptomatic testing	26%	100%	1620
Poissy et al.[27#]	France	100%	107	7	NA, C, m	RT-PCR and CT-scan	59%	57	Symptomatic testing	14%	91%	NA
Pesavento et al.	Italy	3%	322	30	R, C, M	RT-PCR	56	71	Symptomatic testing	13%	100%	1279
Pizzolo et al.[109]	Italy	0%	42	NA	P, C, m	RT-PCR	67%	66	Systematic testing	NA	NA	NA
Poyiadji et al.[110]	USA	25%	328	NA	R, NC, M	RT-PCR	46%	61	CTPA series	9%	37%	NA

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Rali et al.[111]	USA	NA	703	NA	R, C, m	RT-PCR and CT-scan	NA	NA	Symptomatic testing	NA	100%	NA
Rauch et al.[112#]	France	31%	243	30	P, C, m	RT-PCR and CT-scan	64	64%	Symptomatic testing	13%	100%	1000
Rieder et al.[113]	Germany	16%	49	30	P, C, m	RT-PCR	61%	60	Symptomatic testing	6%	NA	1200
Ren et al.[114]	China	100%	48	23	P, NC	NA	54%	70	Asymptomatic screening	31%	98%	3480
Shah et al.[115]	UK	100%	187	20	R, C, M	RT-PCR and CT-scan	66%	57	Symptomatic screening	31%	100%	2587
Shahjoue et al.[116]	Intern.	NA	6356	NA	NA, C, m	RT-PCR and CT-scan	59%	58	Symptomatic screening	NA	NA	NA
Santoliquido et al.[117]	Italy	0%	84	24	P, C, m	RT-PCR	73%	68	Asymptomatic screening	10%	100%	4108
Soumagne et al.[118]	France, Belgium	100%	375	28	NA, C, M	RT-PCR	77%	62	Symptomatic testing	36%	NA	NA
Siepmann et al.[119]	Germany	23%	165	NA	R, C, M	RT-PCR	49	67	Symptomatic testing	20%	NA	900

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Stoneham et al.[120]	UK	NA	274	NA	R, C, m	RT-PCR and CT-scan	NA	NA	Symptomatic testing	NA	NA	NA
Stefely et al.	USA	100%	102	78	P, C, m	RT-PCR	67%	68	Symptomatic testing	22%	100%	2849
Stessel et al.[121]	Belgium	100%	82	30	P, C, m	RT-PCR	82%	66	Asymptomatic screening	26%	100%	NA
Studart-Neto et al.[122]	Brazil	NA	1208	NA	R, C, m	RT-PCR	NA	NA	Symptomatic testing	NA	NA	NA
Taccone et al.[123]	Belgium	100%	82	27	P, C, m	RT-PCR	NA	NA	Symptomatic testing	NA	100%	NA
Tavazzi et al.[54]	Italy	100%	54	NA	NA, C, m	NA	83%	68	Symptomatic testing	NA	100%	NA
Thomas et al.[7]	UK	100%	63	8	R, C, m	RT-PCR	NA	NA	Symptomatic testing	16%	100%	NA
Torres-Machorro et al.[124]	Mexico	100%	30	<9	P, C, m	NA	77%	62	Asymptomatic screening	20%	100%	NA
Trigonis et al.[125]	USA	100%	45	NA	R, NC, m	NA	NA	61	Symptomatic testing	NA	100%	4046
Trimaille et al.[126]	France	25%	289	12	NA, C, m	RT-PCR and CT-scan	59%	62	Symptomatic testing	12%	NA	3874

Study	Country	Patients in ICU	Nb of patients	Mean follow-up (days)	Design	Diagnostic of COVID-19	Male sex	Mean age (y)	Diagnosis of thrombotic event	Death rate	AG	D-Dimer (µg/L)
Violi et al.	Italy	73%	93	15	NA, NA, m	RT-PCR	81%	68	Symptomatic testing	NA	100%	3166
Voicu et al.[127]	France	100%	56	10	P, C, m	NA	75%	NA	Asymptomatic screening	NA	100%	NA
Whyte et al.[128]	UK	16%	1477	NA	R, C, m	NA	NA	NA	Symptomatic testing	16%	NA	NA
Xing et al.[129]	China	55%	20	28	NA, NA, m	NA	NA	NA	Asymptomatic screening	NA	NA	NA
Yaghi et al.[130]	USA	NA	3556	NA	R, C, M	NA	NA	NA	Symptomatic testing	NA	NA	NA
Yu et al.[131]	China	NA	142	31	R, C, m	RT-PCR and serology	57%	62	Asymptomatic screening	23%	26%	2600
Zangrillo et al.[132]	Italy	100%	73	19	R, C, m	RT-PCR	84%	61	Symptomatic testing	23%	100%	1010
Zermatten et al.	Switzerland	100%	100	NA	R, NC, m	RT-PCR	74%	64		28%	100%	6888
Zhang et al.[133]	China	11%	143	19	R, C, m**	RT-PCR	74%	63	Asymptomatic screening	22%	37%	NA
Zhang et al.[134]	China	38%	28	NA	R, NA, M**	RT-PCR	61%	65	Symptomatic testing	29%	NA	NA

AG, anticoagulation (curative or prophylactic dose); C, consecutive; CT-scan: computerized tomography scanner; DVT: deep venous thrombosis; Intern: international; m, monocentric; M, multicentric; NA, not available; Nb, number; NC, non-consecutive; P, prospective; PE, pulmonary embolism, R, retrospective;

RT-PCR: reverse transcriptase- polymerase chain reaction; UK, United Kingdom; VTE, venous thromboembolism; y, years. * patients with lung transplant ** patients with active cancer £ Screening of DTV in 55 patients + patients having D-dimer test @ patients with D-dimer >1 µg/mL ++ patients receiving anakinra µ traveler series # and ## patients overlapped between series.

Table S2 – Quality assessment using the MINORS tools

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Aleva et al.	1	2	0	0	0	2	0	0	5
Annie et al.	2	2	1	2	0	1	0	0	8
Alharty et al.	2	2	2	2	0	2	0	0	10
Alonso-Fernandez et al.	1	1	2	2	0	0	2	0	8
Artifoni et al.	1	0	1	2	0	2	1	0	7
Al-Samkari et al.	2	1	1	2	0	0	0	0	6
Aversa et al.	0	2	0	0	0	2	2	2	8
Beigel et al.	1	2	2	0	0	2	1	0	8
Benito et al.	2	2	2	2	0	0	0	0	8
Betoule et al.	2	0	0	0	0	0	0	0	2
Beun et al.	1	0	0	0	0	0	0	0	1
Bilaloglu et al.	2	2	0	0	0	0	0	0	4
Bompard et al.	1	1	1	2	0	0	0	0	5
Bozzani et al.	2	0	0	0	0	0	0	0	2

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Campochiaro et al.	1	0	1	0	0	2	2	0	6
Cantador et al.	2	0	1	0	0	0	0	0	3
Cattaneo et al.	2	1	1	0	0	1	2	0	7
Cho et al.	2	2	1	0	0	0	0	0	5
Choi et al.	2	2	1	2	0	1	0	0	8
Cui et al.	2	0	1	0	0	1	0	0	4
Demelo-Rodríguez et al.	2	0	2	2	2	2	2	0	12
Desborough et al.	2	1	1	2	0	0	2	0	8
Dubois-Silva et al.	2	2	1	2	0	0	0	0	7
Dumantepe et al.	2	2	1	2	0	0	2	0	9
Du et al.	1	1	2	0	0	0	0	0	4
Espallargas et al	2	2	1	2	0	0	0	0	7
Etkin et al.	2	2	1	0	0	0	0	0	5
Fan et al.	2	1	1	2	0	2	0	0	8
Fauvel et al.	2	2	1	2	0	0	2	0	9

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Fraissé et al.	2	2	1	0	0	0	2	0	7
Freund et al.	2	0	1	2	0	0	0	0	5
Fridman et al.	2	0	0	0	0	0	0	0	2
Galaneo-Valle et al.	2	2	2	2	2	2	2	0	14
Gervaise et al.	1	2	1	2	2	0	0	0	8
Giorgi-Pierfranceschi et al.	2	0	0	0	0	1	0	0	3
Grandmaison et al.	2	2	2	0	0	0	0	0	6
Hanif et al.	2	2	1	0	0	1	0	0	6
Helms et al.	2	2	2	2	1	1	2	0	12
Hippensteel et al.	2	1	1	2	0	1	2	0	9
Huet et al.	1	2	2	0	0	0	0	0	5
Jimenez-Guiu et al.	2	2	2	2	1	0	0	0	9
Kartsios et al.	2	2	1	0	0	0	0	0	5
Klok et al.	2	0	0	2	0	1	2	0	7
Koleitat et al.	2	2	1	0	0	1	0	0	6

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Inciardi et al.	1	2	1	0	0	1	0	0	5
Larsen et al.	2	0	2	2	0	2	2	0	10
Leonard-Lorant et al.	1	2	2	2	0	2	1	0	10
Lejeune et al.	2	2	1	2	2	1	0	0	10
Lendorf et al.	1	2	1	0	0	0	0	0	4
Llitjos et al.	2	2	1	2	2	0	2	0	11
Lodigiani et al.	2	2	1	2	0	1	0	0	8
Longchamp et al.	2	2	2	2	0	0	2	0	10
Longhitano et al.	2	2	1	0	0	0	0	0	5
Li et al.	2	2	1	2	0	0	0	0	7
Maatman et al.	2	2	1	2	0	0	2	0	9
Mattioli et al.	1	2	1	0	0	2	2	0	8
Marone et al.	2	2	2	2	0	0	0	0	8
Mei et al.	2	0	1	2	0	1	0	0	6
Mestre-Gomez et al.	2	0	1	2	0	0	0	0	5

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Middeldorp et al.	2	2	1	2	2	1	2	0	12
Moll et al.	2	0	1	2	0	1	0	0	6
Monfardini et al.	2	2	1	2	2	0	0	0	9
Mouhat et al.	2	2	1	2	2	0	0	0	9
Mueller-Peltzer et al.	2	1	1	2	2	0	0	0	8
Nahum et al.	2	2	2	2	0	0	2	0	10
Naygamon et al.	1	2	1	0	0	0	0	0	4
Patell et al.	2	2	1	2	0	1	0	0	8
Pavoni et al.	2	1	0	2	0	2	2	0	9
Pesavento et al.	2	2	1	2	0	2	2	0	11
Piagnereli et al.	1	0	0	0	0	0	0	0	1
Pizzolo et al.	2	2	2	2	0	0	0	0	8
Poissy et al.	2	2	0	0	0	1	2	0	7
Poyadji et al.	1	1	1	2	0	0	2	0	7
Rali et al.	2	2	1	2	0	0	0	0	6

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Rauch et al.	2	2	2	0	0	2	2	0	10
Rieder et al.	2	2	2	2	0	2	2	0	12
Ren et al.	2	1	2	2	2	1	2	0	12
Saontoliquido et al.	2	2	2	2	0	1	0	0	9
Shah et al.	2	2	1	2	0	1	2	0	10
Shahjoue et al.	2	2	0	2	0	0	0	0	6
Siepmann et al.	2	1	2	2	0	0	0	0	7
Soumagne et al.	2	2	0	0	0	1	0	0	5
Stefely et al.	2	2	2	0	0	2	2	0	10
Stessel et al.	2	2	2	2	0	2	2	0	12
Stoneham et al.	2	2	1	2	0	0	0	0	7
Studart-Neto et al.	2	2	1	2	0	0	0	0	7
Taccone et al.[123]	2	2	2	2	2	0	2	0	12
Tavazzi et al.	2	2	0	0	0	0	2	0	6
Thomas et al.	2	2	1	0	0	1	2	2	10

Study	Aim[a]	Rate[b]	Data[c]	Measure[d]	Bias[e]	Time[f]	Loss[g]	Size[h]	Total[i]
Torres-Machorro et al.	2	2	2	2	0	0	0	0	8
Trigonis et al.	2	1	1	2	0	0	0	0	6
Trimaille et al.	2	2	0	2	0	1	0	0	7
Voicu et al.	2	2	2	2	0	1	2	0	11
Xing et al.	2	0	0	2	0	2	2	0	8
Violi et al.	2	0	0	0	0	0	0	0	2
Whyte et al.	2	2	1	2	0	0	2	0	9
Yaghi et al.	2	2	1	2	0	0	0	0	7
Yu et al.	2	2	1	2	0	2	0	0	9
Zangrillo et al.	1	2	1	0	0	1	2	0	7
Zermatten	2	0	1	2	0	0	0	0	5
Zhang et al.	2	2	1	2	0	1	1	0	9
Zhang et al.	2	1	1	0	0	0	0	0	4

The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal score being 16 for non-comparative studies.

[a] Clearly stated aim for VTE assessment (0, 1, 2 points) [b] Inclusion of consecutive patients (0, 1, 2) [c] Prospective collection of data [d] Endpoint appropriate to VTE (use of CPTA and DUS) (0, 2) [e] Unbiased assessment of the study endpoint (i.e. double blind evaluation) (0, 2) [f] Follow-up period ≥28 days (0, 1 ,2) [g] Loss of follow-up <5% (0, 1, 2) [h] Prospective calculation of study size (0, 2) [I] Total for non-comparative studies

Table S3 – Subgroup analysis to explore heterogeneity in estimate of arterial thromboembolism prevalence

	Studies (k)	Patients (n)	Prevalence; 95% confidence interval (%)	I^2	p-value
Approach to ATE diagnosis	-	-	-	-	-
Patients in ICU					0.27
>70%	11	1,430	5.1 (2.8-8.1)	80%	
≤70%	8	6,819	2.8 (0.5-6.7)	98%	
Prospective series					0.06
Yes	2	393	1.7 (0.7-3.3)	3%	
No/unknown	17	7,856	4.3 (2.1-7.1)	96%	
Multicentric series					0.91
Yes	5	949	4.2 (1.3-8.7)	86%	
No	14	7,300	3.9 (1.6-7.1)	96%	
Consecutive series					0.78
Yes	10	2,540	3.6 (1.9-6.0)	85%	
No/unknown	9	5,709	4.2 (1.2-6.0)	85%	

ICU: intensive care unit; ATE: arterial thromboembolism -: all studies used symptomatic testing.

Table S4 – Metaregression to explore heterogeneity in estimate of arterial thromboembolism prevalence. R^2 estimates the amount of heterogeneity accounted for by the moderators.

	Number of studies	**Beta (95%CI)***	**Intercept****	**p-value**	**R^2**
Number of patients[$]	19	0.0013 (-0.0007; 0.0034)	0.0346	0.20	17%
Proportion of patients in ICU	18	0.0001 (-0.0004 ; 0.0007)	0.0366	0.6718	0%
MINORS score	18	0.0008 (-0.0050; 0.0066)	0.7840	0.7840	0%
D-dimers	-	-	-	-	-
Proportion of patients receiving anticoagulation	13	0.0001 (-0.0025; 0.0027)	0.0221	0.9342	0%
Proportion of man	15	0.0010 (-0.0006 ; 0.0027)	-0.0295	0.2227	0%

*Beta signification: prevalence increase or decrease for the augmentation of one unit of the variable tested; ** Intercept signification: rate of venous thromboembolism for a variable with null value; [$] per increase of 100 patients; -: less than 10 studies reported D-dimers.